NICE’s track record in cancer drugs: the impact of the CDF and interim fundingLeela Barham looks back to before the Cancer Drugs Fund and how recommendations have changed through CDF 1.0 Share XNICE’s track record in cancer drugs: the impact of the CDF and interim fundinghttps://pharmaphorum.com/views-and-analysis/nices-track-record-in-cancer-drugs-the-impact-of-the-cdf-and-interim-funding/
NICE numbers at 20Leela Barham takes a look at NICE’s stats on Technology Appraisals to see how the agency has changed Share XNICE numbers at 20https://pharmaphorum.com/views-analysis-market-access/nice-numbers-20/
VPAS 2024: What should industry consider next time?The UK pharmaceutical industry is just getting to grips with working under two new approaches to regulating branded Share XVPAS 2024: What should industry consider next time?https://pharmaphorum.com/views-analysis-market-access/vpas-2024-what-should-industry-consider-next-time/
Keeping up the PACE at the Scottish Medicines Consortium (SMC)There are many ways that patient centricity could be delivered when doing a health technology assessment (HTA). The Share XKeeping up the PACE at the Scottish Medicines Consortium (SMC)https://pharmaphorum.com/views-analysis-market-access/keeping-up-the-pace-at-the-scottish-medicines-consortium-smc/
The shadow of Brexit on speed of accessNo-one can miss the ongoing saga that is the UK’s exit from the European Union (EU). The uncertainties Share XThe shadow of Brexit on speed of accesshttps://pharmaphorum.com/views-analysis-market-access/the-shadow-of-brexit-on-speed-of-access/
Access to new medicines in Scotland: a perennial issueAccess to new medicines in Scotland – just as it would seem is the case everywhere – is Share XAccess to new medicines in Scotland: a perennial issuehttps://pharmaphorum.com/views-and-analysis/access-to-new-medicines-in-scotland-a-perennial-issue/
Mandatory or voluntary? A sticking point for European HTAThe long road to unified European Health Technology Assessment (HTA) is continuing. It has become clear that the Share XMandatory or voluntary? A sticking point for European HTAhttps://pharmaphorum.com/views-analysis-market-access/mandatory-or-voluntary-a-sticking-point-for-european-hta/
Late to the party but we brought friends: BeneLuxA’s horizon scanning initiativeIt can feel good to know what is coming your way; that’s no different for new medicines and Share XLate to the party but we brought friends: BeneLuxA’s horizon scanning initiativehttps://pharmaphorum.com/views-analysis-market-access/joint-horizon-scanning/
A payer’s perspective on value-based contracting (VBC)What payer wouldn’t want to ensure that they pay for value when buying drugs? If the emerging trend Share XA payer’s perspective on value-based contracting (VBC)https://pharmaphorum.com/views-analysis-market-access/payers-perspective-value-based-contracting-vbc/
